// App-Quantinova.ai

TPS5107 : A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone (AP) for patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on abiraterone.

Researchers

Presenter

  • Jianqing Lin

Principal Investigators

  • Ashwin Reddy Sama

  • Zhaomei Mu

  • Benjamin E Leiby

  • Nancy Lewis

  • Massimo Cristofanilli

  • William Kevin Kelly

Medical Centers

  • The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA

  • Kimmel Cancer Center Jefferson, Philadelphia, PAKimmel Cancer Center, Thomas Jefferson University, Philadelphia, PAThomas Jefferson University, School of Medicine, Philadelphia, PA

  • Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA

  • Thomas Jefferson University, Philadelphia, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Bladder Cancer

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • Enolase 2

  • Circulating tumor cells

  • Poly(ADP-Ribose) Polymerase 1

  • Prostate specific antigen

Drug/Treatment

  • Methotrexate

  • Cabazitaxel

  • CB-7598

  • Vinblastine

  • Doxorubicin

  • Prednisone

  • Alisertib

  • Cisplatin

  • Androgen Tear

Outcome

  • Unknown

Study Design

  • open label

Phase

  • I/II

Study Id's

  • NCT01848067

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved